Squawk on the Street Cramer's Morning Take: Eli Lilly 5/22/25
May 22, 2025
The podcast tackles the healthcare sector's struggles, focusing on Eli Lilly's decline amid volatility. Amid this backdrop, they discuss the promising GLP-1 medication, emphasizing its benefits beyond diabetes and weight loss. Insights from a cardiologist shed light on its potential for longevity and address misconceptions surrounding its effectiveness in the market.
AI Snips
Chapters
Transcript
Episode notes
Healthcare Sector Disappointment
- Healthcare sector has been disappointing this year despite optimism. - Even strong performers like Eli Lilly have seen setbacks recently.
Broad Potential of GLP-1 Drugs
- GLP-1 drugs like Eli Lilly's are highly endorsed for broad health benefits beyond diabetes. - These drugs may extend life and improve health globally, contrasting with sellers' skepticism.
Consider Buying Eli Lilly Stock
- Buying Eli Lilly stock at current lower levels is advisable due to the drug’s promising impact. - The drug fights weight gain and comorbidities, making it essential for many patients worldwide.